JSPR
Jasper Therapeutics, Inc. NASDAQ Listed Jan 10, 2020$0.49
-2.49%
vs $0.50
Mkt Cap $7.5M
52w Low $0.45
0.6% of range
52w High $6.82
50d MA $0.78
200d MA $1.51
P/E (TTM)
-0.1x
EV/EBITDA
—
P/B
2.3x
Debt/Equity
0.3x
ROE
-1826.1%
P/FCF
-0.1x
RSI (14)
38.40
ATR (14)
$0.07
Beta
3.20
50d MA
$0.78
200d MA
$1.51
Avg Volume
579.9K
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
2200 Bridge Pkwy · Redwood City, CA 94065 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | AMC | -0.46 | -0.04 | +91.3% | 0.96 | -4.5% | -11.4% | -5.1% | +1.5% | +6.6% | +0.0% | — |
| Mar 30, 2026 | AMC | -0.79 | -0.32 | +59.5% | 0.90 | -5.0% | -2.6% | -8.7% | -14.0% | -0.5% | -2.4% | — |
| Nov 10, 2025 | AMC | -1.01 | -1.13 | -11.9% | 1.78 | +0.0% | -4.5% | +4.1% | -9.0% | +4.3% | +6.5% | — |
| Aug 13, 2025 | AMC | -1.20 | -1.74 | -45.0% | 2.97 | -2.0% | +2.0% | +2.6% | -5.8% | -2.7% | +0.0% | — |
| May 12, 2025 | AMC | -1.17 | -1.41 | -20.5% | 4.74 | +4.2% | +1.7% | +0.6% | +0.4% | +1.2% | +1.8% | — |
| Feb 27, 2025 | AMC | -1.27 | -1.62 | -27.6% | 5.67 | +0.4% | +4.6% | -5.9% | -0.9% | +2.7% | -4.2% | — |
| Nov 7, 2024 | AMC | -1.09 | -1.24 | -13.8% | 22.69 | -3.0% | +8.1% | +0.8% | -3.5% | -4.5% | -3.1% | — |
| Aug 13, 2024 | AMC | -1.09 | -0.97 | +11.0% | 18.85 | +2.0% | -4.6% | +0.7% | -0.1% | +4.1% | -0.5% | — |
| May 14, 2024 | AMC | -1.26 | -1.03 | +18.3% | 20.92 | -1.5% | +3.3% | +5.8% | +0.7% | +0.9% | -0.6% | — |
| Mar 4, 2024 | AMC | -1.65 | -1.50 | +9.1% | 22.28 | -0.1% | +11.6% | +8.2% | -0.7% | +3.2% | -3.7% | — |
| Nov 9, 2023 | AMC | -1.50 | -1.60 | -6.7% | 7.37 | +3.5% | -6.4% | -4.8% | -4.0% | -8.9% | +6.4% | — |
| Aug 11, 2023 | AMC | -1.30 | -1.50 | -15.4% | 13.90 | +0.0% | -4.3% | +8.3% | -5.6% | +0.7% | +5.8% | — |
| May 12, 2023 | AMC | -1.50 | -1.60 | -6.7% | 15.70 | +0.0% | -0.6% | -0.6% | +7.1% | +7.2% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15 | TD Cowen | Downgrade | Buy → Hold | — | $0.96 | $0.92 | -4.5% | -11.4% | -5.1% | +1.5% | +6.6% | +0.0% |
| Apr 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $0.88 | $0.89 | +1.3% | -8.7% | -14.0% | -0.5% | -2.4% | +5.9% |
| Nov 11 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $1.78 | $1.78 | +0.0% | -4.5% | +4.1% | -9.0% | +4.3% | +6.5% |
| Sep 22 | BTIG | Maintains | Buy → Buy | — | $2.50 | $2.50 | +0.0% | +1.6% | -5.5% | -2.9% | +0.0% | +6.0% |
| Sep 22 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.50 | $2.50 | +0.0% | +1.6% | -5.5% | -2.9% | +0.0% | +6.0% |
| Sep 22 | Evercore ISI | Maintains | Outperform → Outperform | — | $2.50 | $2.50 | +0.0% | +1.6% | -5.5% | -2.9% | +0.0% | +6.0% |
| Aug 15 | UBS | Maintains | Buy → Buy | — | $3.03 | $3.08 | +1.7% | +2.6% | -5.8% | -2.7% | +0.0% | +3.5% |
| Jul 8 | BMO Capital | Downgrade | Outperform → Market Perform | — | $3.04 | $3.11 | +2.3% | -0.7% | +21.9% | -3.5% | -1.1% | -1.1% |
| Jul 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.04 | $3.11 | +2.3% | -0.7% | +21.9% | -3.5% | -1.1% | -1.1% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $3.04 | $3.11 | +2.3% | -0.7% | +21.9% | -3.5% | -1.1% | -1.1% |
| Jul 7 | William Blair | Downgrade | Outperform → Market Perform | — | $6.77 | $2.30 | -66.0% | -55.1% | -0.7% | +21.9% | -3.5% | -1.1% |
| Jul 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.77 | $2.30 | -66.0% | -55.1% | -0.7% | +21.9% | -3.5% | -1.1% |
| Jul 7 | BTIG | Maintains | Buy → Buy | — | $6.77 | $2.30 | -66.0% | -55.1% | -0.7% | +21.9% | -3.5% | -1.1% |
| Jul 7 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $6.77 | $2.30 | -66.0% | -55.1% | -0.7% | +21.9% | -3.5% | -1.1% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.85 | $4.85 | +0.0% | +0.4% | +1.2% | +1.8% | +0.4% | -4.4% |
| May 13 | UBS | Maintains | Buy → Buy | — | $4.74 | $4.94 | +4.2% | +1.7% | +0.6% | +0.4% | +1.2% | +1.8% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.28 | $5.25 | -0.6% | +1.3% | +0.7% | -0.2% | +2.0% | +2.9% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.99 | $7.12 | +1.9% | +0.9% | -5.1% | -12.3% | -0.9% | -8.2% |
| Jan 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.99 | $7.12 | +1.9% | +0.9% | -5.1% | -12.3% | -0.9% | -8.2% |
| Jan 9 | RBC Capital | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Jan 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $19.27 | $19.82 | +2.9% | +8.3% | -15.1% | -60.5% | +0.9% | -5.1% |
| Dec 23 | RBC Capital | Maintains | Outperform → Outperform | — | $21.57 | $21.58 | +0.0% | +2.5% | -1.9% | +3.6% | -1.1% | -5.8% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.95 | $20.06 | +0.6% | -0.3% | -1.8% | +12.6% | +1.5% | -2.6% |
| Oct 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $16.58 | $16.62 | +0.2% | +10.3% | -0.5% | +9.1% | +1.1% | -0.7% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.58 | $16.62 | +0.2% | +10.3% | -0.5% | +9.1% | +1.1% | -0.7% |
| Sep 27 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $18.84 | $19.07 | +1.2% | -0.1% | -0.1% | -8.0% | -1.7% | -3.8% |
| Aug 26 | Evercore ISI | Maintains | Outperform → Outperform | — | $19.29 | $19.48 | +1.0% | +3.6% | +1.3% | -1.5% | +0.7% | +8.5% |
| Aug 14 | RBC Capital | Maintains | Outperform → Outperform | — | $18.85 | $19.22 | +2.0% | -4.6% | +0.7% | -0.1% | +4.1% | -0.5% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.77 | $17.13 | +2.1% | +12.4% | -4.6% | +0.7% | -0.1% | +4.1% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.82 | $15.31 | -9.0% | -1.8% | +0.6% | -2.1% | +0.9% | -0.5% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.02 | $23.22 | +0.9% | +0.9% | -0.6% | +3.1% | +0.0% | +0.4% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.92 | $20.60 | -1.5% | +3.3% | +5.8% | +0.7% | +0.9% | -0.6% |
| Mar 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $26.90 | $27.50 | +2.2% | -0.7% | +3.2% | -3.7% | -2.0% | +3.0% |
| Oct 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.07 | $9.00 | -0.8% | +0.3% | -6.6% | +2.6% | -5.4% | -3.0% |
| Aug 13 | Credit Suisse | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Jun 11 | EF Hutton | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 14 | EF Hutton | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 14 | Credit Suisse | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Mar 9 | EF Hutton | Maintains | Buy → Buy | — | $20.00 | $20.20 | +1.0% | -7.0% | -7.0% | +5.2% | +7.7% | -3.1% |
| Mar 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $20.00 | $20.20 | +1.0% | -7.0% | -7.0% | +5.2% | +7.7% | -3.1% |
| Mar 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $20.00 | $20.20 | +1.0% | -7.0% | -7.0% | +5.2% | +7.7% | -3.1% |
| Feb 27 | EF Hutton | Maintains | Buy → Buy | — | $17.60 | $17.50 | -0.6% | +8.5% | +1.0% | -1.6% | -0.5% | +1.6% |
| Feb 15 | EF Hutton | Maintains | Buy → Buy | — | $17.80 | $17.50 | -1.7% | -2.0% | +4.9% | -0.5% | -1.1% | -0.6% |
| Feb 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $19.20 | $19.10 | -0.5% | -1.6% | -2.1% | -5.4% | +1.7% | +2.8% |
| Jan 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $15.90 | $19.60 | +23.3% | +3.8% | +0.0% | +0.0% | +7.9% | +7.3% |
| Jan 10 | EF Hutton | Maintains | Buy → Buy | — | $15.90 | $19.60 | +23.3% | +3.8% | +0.0% | +0.0% | +7.9% | +7.3% |
| Nov 13 | Oppenheimer | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Nov 1 | EF Hutton | Maintains | Buy → Buy | — | $7.30 | $7.60 | +4.1% | +3.3% | -3.2% | +0.0% | -4.1% | +1.4% |
| Jul 12 | Credit Suisse | Maintains | Outperform → Outperform | — | $22.50 | $23.60 | +4.9% | +2.2% | +0.0% | -13.0% | -2.5% | +0.0% |
| May 12 | Credit Suisse | Maintains | Outperform → Outperform | — | $30.20 | $29.40 | -2.6% | -3.0% | +2.0% | -0.7% | +0.0% | +1.3% |
No insider trades available.
8-K
Jasper Therapeutics, Inc. -- 8-K Filing
Jun 9
8-K · 7.01
! Medium
Jasper Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 1
8-K · 5.02
!!! Very High
Jasper Therapeutics, Inc. -- 8-K 5.02: Executive Change
May 21
8-K · 2.02
!! High
Jasper Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K
Unknown — 8-K Filing
Jasper Therapeutics released 2025 year-end results and corporate updates on its lead candidate briquilimab; investors should monitor clinical progress and cash runway as a pre-revenue biotech company.
Mar 30
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Small Cap Core Fund | 3,638 | $3K | Mar 2026 |
| 2 | AST Small-Cap Equity Portfolio | 780 | $1K | Dec 2025 |
Valuation
Market Cap
$7.5M
Enterprise Value
-$21.2M
P/E (TTM)
-0.14x
Forward P/E
—
PEG Ratio
0.02x
P/B
2.26x
P/S
—
P/FCF
-0.10x
EV/EBITDA
—
Shares Out
15.3M
Financials (TTM)
Revenue
$0
Net Income
-$55.7M
EBITDA
-$54.9M
Free Cash Flow
-$77.2M
Op Cash Flow
-$77.2M
EPS Basic
$-3.95
EPS Diluted
$-3.54
EPS Forward
$-1.75
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$35.8M
Total Liab.
$31.6M
Total Equity
$4.2M
Cash
$28.7M
LT Debt
$0
Book Value/Sh
$0.22
Debt/Equity
0.30x
Current Ratio
2.62
Quick Ratio
2.62
Returns & Growth
ROE
-1826.1%
ROA
-211.9%
ROIC
-338.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+19.2%
Price Returns
2W
-13.6%
1M
-11.4%
3M
-39.9%
6M
-54.9%
12M
-84.9%
Technicals
52W High
$6.82
52W Low
$0.45
50d MA
$0.78
200d MA
$1.51
RSI (14)
38.40
ATR (14)
$0.07
Beta
3.20
Avg Volume
580K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$41.67
High
$65.00
Low
$3.00
Median
$55.50
Data updated apr 25, 2026 5:03pm
· Source: financialmodelingprep.com